NanoVation Therapeutics

About NanoVation Therapeutics

NanoVation Therapeutics develops customized lipid nanoparticle (LNP) formulations for the targeted delivery of nucleic acids, enabling effective treatment of diseases beyond liver tissues. Their technology addresses the challenge of safe and efficient nucleic acid delivery, facilitating the advancement of genetic medicines into clinical applications.

```xml <problem> Current nucleic acid delivery methods face challenges in safely and efficiently targeting tissues beyond the liver, limiting the therapeutic potential of genetic medicines. Existing lipid nanoparticle (LNP) technologies often lack the specificity and stability required for effective extrahepatic delivery. </problem> <solution> NanoVation Therapeutics develops customized, scalable lipid nanoparticle (LNP) formulations for targeted nucleic acid delivery to a variety of tissues. Their next-generation platform technologies overcome the limitations of existing approaches, enabling the development of genetic medicines for diseases beyond the liver. NanoVation's long-circulating LNP (lcLNP™) technology demonstrates improved potency, safety, and stability in preclinical studies. The company offers comprehensive solutions spanning novel lipid design, RNA modifications, and LNP compositions, empowering partners to rapidly develop their genetic medicines. </solution> <features> - Scalable, nucleic acid-agnostic LNP formulations customized for specific targets, payloads, and routes of administration - Extensive library of novel lipids and LNP compositions - Long-circulating LNP (lcLNP™) technology for improved potency, safety, and stability - Toolbox for LNP-based genetic medicine development, including novel lipid design, RNA modifications, and LNP compositions - Expertise in mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization </features> <target_audience> The primary customers are pharmaceutical and biotechnology companies developing genetic medicines, particularly those focused on extrahepatic delivery and novel LNP formulations. </target_audience> ```

What does NanoVation Therapeutics do?

NanoVation Therapeutics develops customized lipid nanoparticle (LNP) formulations for the targeted delivery of nucleic acids, enabling effective treatment of diseases beyond liver tissues. Their technology addresses the challenge of safe and efficient nucleic acid delivery, facilitating the advancement of genetic medicines into clinical applications.

Where is NanoVation Therapeutics located?

NanoVation Therapeutics is based in Vancouver, Canada.

When was NanoVation Therapeutics founded?

NanoVation Therapeutics was founded in 2020.

Location
Vancouver, Canada
Founded
2020
Employees
42 employees
Major Investors
Convergent Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

NanoVation Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

NanoVation Therapeutics develops customized lipid nanoparticle (LNP) formulations for the targeted delivery of nucleic acids, enabling effective treatment of diseases beyond liver tissues. Their technology addresses the challenge of safe and efficient nucleic acid delivery, facilitating the advancement of genetic medicines into clinical applications.

nanovationtx.com7K+
cb
Crunchbase
Founded 2020Vancouver, Canada

Funding

Major Investors

Convergent Ventures

Team (40+)

No team information available.

Company Description

Problem

Current nucleic acid delivery methods face challenges in safely and efficiently targeting tissues beyond the liver, limiting the therapeutic potential of genetic medicines. Existing lipid nanoparticle (LNP) technologies often lack the specificity and stability required for effective extrahepatic delivery.

Solution

NanoVation Therapeutics develops customized, scalable lipid nanoparticle (LNP) formulations for targeted nucleic acid delivery to a variety of tissues. Their next-generation platform technologies overcome the limitations of existing approaches, enabling the development of genetic medicines for diseases beyond the liver. NanoVation's long-circulating LNP (lcLNP™) technology demonstrates improved potency, safety, and stability in preclinical studies. The company offers comprehensive solutions spanning novel lipid design, RNA modifications, and LNP compositions, empowering partners to rapidly develop their genetic medicines.

Features

Scalable, nucleic acid-agnostic LNP formulations customized for specific targets, payloads, and routes of administration

Extensive library of novel lipids and LNP compositions

Long-circulating LNP (lcLNP™) technology for improved potency, safety, and stability

Toolbox for LNP-based genetic medicine development, including novel lipid design, RNA modifications, and LNP compositions

Expertise in mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization

Target Audience

The primary customers are pharmaceutical and biotechnology companies developing genetic medicines, particularly those focused on extrahepatic delivery and novel LNP formulations.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.